medmix AG (MEDX) AI Stock Analysis

• Market Cap: CHF451.41M
• Dividend Yield: 4.59%
• Average Volume (3M): 63.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: -2.42%
• EPS Growth: -222.68%
• Country: CH
• Employees: 2,684
• Sector: Healthcare
• Sector Strength: 40
• Industry: Industrial - Machinery
• EPS (TTM): 0.39
• Shares Outstanding: 41,262,370
• 10 Day Avg. Volume: 52,376
• 30 Day Avg. Volume: 63,443
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF11.00
• Price Target Upside: 0.55% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: CHF11.00 ▲(0.55% Upside)

The overall stock score for medmix AG is primarily impacted by its mixed financial performance, with challenges in profitability and increasing leverage. Technical analysis shows bearish signals, and valuation concerns arise from a negative P/E ratio despite a high dividend yield. These factors collectively suggest caution for investors.

medmix AG Business Overview & Revenue Model

Company Description

medmix AG (MEDX) is a Swiss-based company specializing in high-precision delivery devices across various sectors, including healthcare, consumer and industrial markets. The company offers a wide range of products such as injection systems, dental applicators, and industrial dispensing solutions, focusing on enhancing the performance and reliability of fluid delivery systems.

How the Company Makes Money

medmix AG generates revenue through the sale of its high-precision delivery devices tailored to healthcare, consumer, and industrial sectors. Key revenue streams include the manufacturing and distribution of injection systems for the healthcare industry, dental applicators for dental care, and advanced dispensing solutions for industrial applications. The company's earnings are bolstered by partnerships with leading firms in these sectors, allowing them to expand their market reach and enhance product innovation. Additionally, medmix AG benefits from long-term contracts and recurring sales owing to the consumable nature of some of its products, ensuring a steady revenue flow.

medmix AG Financial Statement Overview

Summary

Mixed financial health with strong cash flow operations but challenges in profitability and increased leverage. Revenue growth is weak, and operational efficiency needs improvement.

Income Statement

The company shows a stable gross profit margin of approximately 33% over the years, but the net profit margin has been volatile, recently turning negative in the latest period. Though revenue has shown minimal fluctuation, the overall growth trajectory is weak. EBIT and EBITDA margins suggest operational challenges, with declining EBIT over recent periods.

Balance Sheet

The company's debt-to-equity ratio has increased over time, indicating higher leverage, while the equity ratio has slightly decreased. Return on equity has diminished, reflecting reduced profitability. The balance sheet reveals potential risks from increased liabilities relative to equity.

Cash Flow

The company has improved its cash flow operations, evident from positive operating cash flow growth. However, free cash flow growth has been inconsistent, although it has turned positive recently. The operating cash flow to net income ratio is strong, indicating efficient cash generation relative to net income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	483.90M	486.60M	477.10M	457.30M	351.30M
Gross Profit	159.70M	157.70M	175.40M	181.20M	121.10M
EBITDA	67.60M	71.40M	68.30M	110.60M	60.90M
Net Income	-7.40M	300.00K	11.60M	44.00M	9.60M
Balance Sheet
Total Assets	954.20M	1.01B	1.11B	974.40M	789.90M
Cash, Cash Equivalents and Short-Term Investments	96.20M	130.60M	316.80M	210.00M	46.20M
Total Debt	323.40M	349.70M	473.50M	320.90M	332.30M
Total Liabilities	507.50M	532.40M	601.10M	440.50M	456.50M
Stockholders Equity	436.40M	465.40M	504.80M	533.90M	333.40M
Cash Flow
Free Cash Flow	38.10M	3.20M	9.00M	55.40M	7.50M
Operating Cash Flow	86.60M	56.10M	47.60M	87.30M	50.60M
Investing Cash Flow	-51.50M	-80.60M	-57.00M	-3.30M	4.40M
Financing Cash Flow	-48.60M	-153.80M	116.10M	111.60M	-42.90M

medmix AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.94
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MEDX, the sentiment is Negative. The current price of 10.94 is below the 20-day moving average (MA) of 11.91, below the 50-day MA of 11.71, and above the 200-day MA of 10.35, indicating a neutral trend. The MACD of -0.21 indicates Positive momentum. The RSI at 36.27 is Neutral, neither overbought nor oversold. The STOCH value of 6.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:MEDX.

medmix AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MOVE	75 Outperform	$2.97B	42.57	20.81%	0.46%	13.35%	50.65%
BSLN	73 Outperform	CHF629.66M	8.07		―	32.30%	631.04%
MED	71 Outperform	CHF1.08B	296.23		―	6.05%	449.69%
Sector *	64 Neutral	CHF26.61B	17.43	9.71%	2.36%	21.05%	3.32%
TECN	64 Neutral	CHF1.98B	29.19	4.57%	1.93%	-9.34%	-37.50%
MEDX	49 Neutral	CHF451.41M	―		4.59%	-2.42%	-222.68%

medmix AG Corporate Events

medmix AG Reports Increased Profitability Amid Revenue Decline in H1 2025

medmix AG reported a 6.5% decline in revenue for the first half of 2025, attributed to subdued performance in the Beauty segment and foreign exchange impacts. Despite this, the company achieved increased profitability with an adjusted EBITDA margin of 19.9%, driven by strong growth in the Dental and Surgery segments and the implementation of a Growth and Efficiency program. The company has revised its revenue guidance for 2025 but confirmed its profitability targets, reflecting its strategic pivot towards high-margin healthcare businesses. The leadership team has been strengthened with new appointments, aiming to bolster the company’s focus on innovation and operational excellence.

The most recent analyst rating on (CH:MEDX) stock is a Buy with a CHF18.00 price target. To see the full list of analyst forecasts on medmix AG stock, see the CH:MEDX Stock Forecast page.

medmix AG Achieves Top Climate Leadership Recognition

medmix AG has been recognized as one of only nine Swiss companies to achieve an ‘A’ score in CDP’s annual climate change assessment, highlighting its leadership in environmental performance. This recognition underscores medmix’s commitment to integrating environmental principles across its operations and its strategic focus on sustainable innovation, aiming to set new benchmarks for environmental responsibility in the industry.

The most recent analyst rating on (CH:MEDX) stock is a Buy with a CHF18.00 price target. To see the full list of analyst forecasts on medmix AG stock, see the CH:MEDX Stock Forecast page.